Session Information
Session Title: AA 2022 Posters - Musculoskeletal and Sports Medicine
Session Time: None. Available on demand.
Disclosures: Giorgio A. Negron, MD: No financial relationships or conflicts of interest
Objective: The objective is to report preliminary data on clinical response to a single injection of an amniotic-derived tissue produce (dehydrated cell and protein concentrate [dCPC]) versus corticosteroid (CSI) for the treatment of knee osteoarthritis.
Design: A prospective, randomized controlled single-blinded trial
Setting: Single-center trial at a highly specialized referral center for orthopedics. Enrollment and data collection were performed from November 2018 to May 2021.
Participants: Patients were included if they met the following criteria: age >20 but < 75 years; knee radiographs within 3 months of beginning treatment; diagnosis of knee osteoarthritis with KL grade II, III or IV.
Interventions: The dCPC injectate included 4 cc of saline and 30 mg of dCPC. The steroid injectate included 2 cc of lidocaine, 2 cc of saline and 1 cc 40 mg of Depo- medrol. The procedures were performed under sterile conditions and utilizing ultrasound guidance. Each participant was scheduled for follow-up at 1, 2, 3, 6, 9 and 12 months post-intervention.
Main Outcome Measures: Pain and function were assessed using a visual analog scale (VAS), the Knee Injury and Osteoarthritis Outcome Score (KOOS), and the Emory Quality of Life (EQOL) measure at 1, 2, 3, 6, 9, and 12 months.
Results: Fifty-one patients were enrolled at the time of analysis (27 dCPC, 24 CSI). Both groups demonstrated improvement on the VAS, KOOS and EQOL. Largest differences were observed at 2 (p = .05), 3 (p = .012) and 6 months (p < .001) with a decrease of 1.66 in VAS at 6 months for dCPC (95% CI -2.67 to -.65) and 1.34 (95% CI -2.37 to -.3) for CSI. Time-averaged measures showed no difference between groups (p = .20). Limited data at 9 and 12 months trended toward improvement in the dCPC group.
Conclusions: The dCPC products may be used as a treatment for knee osteoarthritis. Larger trials are warranted.
Level of Evidence: Level I
To cite this abstract in AMA style:
Negron GA, Olufade O, Berrigan W, Sirutis BS. Amniotic Dehydrated Cell and Protein Concentrate Versus Corticosteroid in Knee Osteoarthritis: Preliminary Findings [abstract]. PM R. 2022; 14(S1)(suppl 1). https://pmrjabstracts.org/abstract/amniotic-dehydrated-cell-and-protein-concentrate-versus-corticosteroid-in-knee-osteoarthritis-preliminary-findings/. Accessed September 7, 2024.« Back to AAPM&R Annual Assembly 2022
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/amniotic-dehydrated-cell-and-protein-concentrate-versus-corticosteroid-in-knee-osteoarthritis-preliminary-findings/